Floatz logo

Sargramostim

Progesterone-Receptor Positive Breast Cancer

Fred Hutchinson Cancer Centerprotein_peptidePhase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
42/ 100
Competitive Position
95/ 100

Competitive context

13 Active assets in the Progesterone-Receptor Positive Breast Cancer cohort.

Asset / SponsorPhaseRating
TAMOXIFEN
Jennifer Lee Caswell-Jin
Phase 2BB
Letrozole
Ruth O'Regan
Phase 2BB
Cyclophosphamide
University of Washington
Phase 2B
FILGRASTIM
University of Washington
Phase 2B
Zoledronate
City of Hope Medical Center
Phase 2B

View all 36 →

Same molecule, other indications

Sargramostim is also rated in:

cancer of unknown primary siteDormant
BBB
Indicative ·
72 / 100
View asset →
melanomaDormant
BBB
Indicative ·
72 / 100
View asset →
chronic myeloid leukemiaDormant
BBB
Indicative ·
72 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →